Comparative Treatment Patterns and Outcomes of Fulvestrant versus Everolimus Plus Exemestane for Postmenopausal Metastatic Breast Cancer Resistant to Aromatase Inhibitors in Real-World Experience

Comparative Treatment Patterns and Outcomes of Fulvestrant versus Everolimus Plus Exemestane for Postmenopausal Metastatic Breast Cancer Resistant to Aromatase Inhibitors in Real-World Experience

Yi Li,1,* Yizhao Xie,1,* Chengcheng Gong,1 Yannan Zhao,1 Jian Zhang,1 Sheng Zhang,1 Leiping Wang,1 She Chen,2 Xichun Hu,1 Biyun Wang1 1Department of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, People&...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Li Y, Xie Y, Gong C, Zhao Y, Zhang J, Zhang S, Wang L, Chen S, Hu X, Wang B
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2020
Materias:
fulvestrant
everolimus
exemestane
metastatic breast cancer
endocrine therapy.
Therapeutics. Pharmacology
RM1-950
Acceso en línea:https://doaj.org/article/e1b4f99a21dc4a6780fe74ce220f0b01
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares